Psychedelics & Cannabis

New cohort and global data link teen high-potency cannabis use to higher psychosis, bipolar, and suicide risks. Here's what psychiatrists and mental health clinicians should know in the era of legalization.

In the wake of the FDA fast-track of psychedelic therapies, we want to hear your clinical pearls for our May theme.

The triple-blinded EPISODE trial with active placebo and 4 dosing regimens yielded mixed results, reflecting the challenge of discerning psilocybin effect and distinguishing between enlightenment and expectation.

Read our exclusive interview with Daniel R. Karlin, MD, MA, on the latest executive order, DT120 for the treatment of mental health disorders, and more.

DT120, a pharmaceutical-grade formulation of LSD, shows rapid, lasting anxiety relief—single dose, no therapy—with 48% remission at 12 weeks.

FDA accelerates psychedelic drug development to advance agents for TRD, PTSD, and AUD.

Definium’s CMO says FDA talks stay aligned with their plans for advancing DT120 ODT for the treatment of depression, anxiety, and now PTSD.

Psychedelic therapies surge, but a rushed FDA shortcut risks safety; learn why ibogaine claims need rigorous trials and oversight.

High-potency cannabis surges; psychiatry confronts psychosis risk, dependence, and data gaps—why clinicians must guide safer use now.

A new US-based grant program seeks to create training content for health care providers who want to be able to deliver investigational COMP360 psilocybin treatment.

Guy Goodwin, MD, provides insights into COMP360 psilocybin and recent trial results, as well as psychedelics as a whole and their role in psychiatry.

Compass Pathways reports COMP360 psilocybin shows fast, durable relief in treatment‑resistant depression. Guy Goodwin, MD, shares his insights.

An expert shares why new kratom variants have dangerous implications for substance use disorder.

Data show fast-acting psychedelic therapy for depression with lasting gains—plus the safety questions shaping its future.

See why ketamine boosts outcomes for treatment‑resistant depression.

Discover more on the uses and context of ketamine.

Learn more about developments in COMP360 and psychedelic news.

Psilocybin for depression nears approval; clinicians must manage medication interactions, avoiding lithium and MAOIs while monitoring vital signs and blunted effects.

How does MDMA-assisted therapy rewire fear circuits in PTSD and boost trust? Why has the FDA asked for more safety data? Learn more in this Special Report.

MAPS guidebook maps psychedelic policy: decriminalization vs regulated access, provider hurdles, and equity as states act in 2026.

Psychedelic therapies surge in trials, but safety varies by substance—learn key benefits, risks, and why psychiatric history raises complications.

How are MDMA and psilocybin reshaping PTSD and depression care? Learn more in our Psychedelics Special Report.

IV DMT psychedelic SPL026 reduces major depression in phase 2a.

Phase 3 trial shows COMP360 psilocybin rapidly reduces treatment-resistant depression symptoms with durable effects and good safety, as Compass moves toward FDA review.

New research highlights psilocybin's potential in treating treatment-resistant OCD, while cannabinoids show little evidence of efficacy.